Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
EXTON, Pa., May 03, 2018 -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, will report financial results for the first quarter ended March 31, 2018 and recent operational highlights on Thursday, May 10, 2018 before the open of the U.S. financial markets. Fibrocell will also host a conference call and webcast at 8:30 a.m. EDT on the same day to discuss its financial results and operational highlights. A question-and-answer session will follow Fibrocell’s remarks.
To participate on the live call, please dial 866-548-4713 (domestic) or +1-323-794-2093 (international), and provide the conference code 3897293 five to ten minutes before the start of the call. The conference call will also be webcast live under the investor relations section of Fibrocell's website at www.fibrocell.com/investors/events and will be archived there for 30 days following the call.
About Fibrocell
Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Fibrocell’s most advanced product candidate, FCX-007, is the subject of a Phase 1/2 clinical trial for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also developing FCX-013, the Company’s product candidate for the treatment of moderate to severe localized scleroderma. Fibrocell’s gene therapy portfolio is being developed in collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology. For more information, visit www.fibrocell.com or follow Fibrocell on Twitter at @Fibrocell.
Trademarks
Fibrocell, the Fibrocell logo, and Fibrocell Science are trademarks of Fibrocell Science, Inc. and/or its affiliates. All other names may be trademarks of their respective owners.
Investor & Media Relations Contact:
Karen Casey
484-713-6133
[email protected]
